Summary:
Stocks to watch today, October 1: Aurobindo Pharma, Tech Mahindra, NCC, IRFC, Jio Financial Services, Blue Dart Express and others are in focus after product launches, order wins, management changes, pricing actions, tax notices and strategic corporate developments.
Which stocks are in focus today, October 1?
Indian stocks could see increased activity in several counters following a series of corporate announcements covering new product launches, order wins, management changes, strategic partnerships, pricing actions and regulatory developments.
Stocks to Watch Today: Key Updates
| Stock | Key Development | Why in Focus |
|---|---|---|
| Aurobindo Pharma | U.S. launch of ADQUEY | New dermatology product |
| Tech Mahindra | Bonus issue proposal; Q2 results board meeting | October 15 board meeting |
| NCC | ₹500.22 crore additional September orders | Buildings and transportation orders |
| Highway Infrastructure | ₹220.66 crore toll contract | Gorakhpur Link Expressway |
| Blue Dart Express | 9–12% price hike | Effective January 1, 2027 |
| Symbiotec Pharma | U.S. commercialisation agreement | Two injectable products |
| Lemon Tree Hotels | New hotel in Darjeeling | Portfolio expansion |
| Bata India | New MD & CEO | Management change |
| IRFC | ₹396.91 crore GST show-cause notice | Regulatory development |
| MCX | ₹103.31 crore GST SCN including interest/penalty | Tax dispute |
| Wipro | Alpha Net contract acquisition deadline extended | Deal timeline |
| Infosys | ABN AMRO collaboration extended | AI-led transformation |
| South Indian Bank | New MD & CEO | Management appointment |
| Jio Financial Services | ₹320.05 crore JV investment | Insurance business capital infusion |
Why Are These Stocks in Focus Today?
The October 1 list is driven by several different types of corporate developments:
Product launch: Aurobindo Pharma
Corporate action: Tech Mahindra
Order wins: NCC, Highway Infrastructure
Pricing action: Blue Dart Express
Commercialisation agreement: Symbiotec Pharma
Portfolio expansion: Lemon Tree Hotels
Management changes: Bata India, South Indian Bank
Tax/regulatory notices: IRFC, MCX
Strategic collaboration: Infosys
Transaction timeline: Wipro
Capital infusion: Jio Financial Services
Aurobindo Pharma
Aurobindo Pharma's biopharmaceutical subsidiary, Acrotech Biopharma Inc., has launched ADQUEY (difamilast 1%) ointment in the U.S. The non-steroidal topical treatment is indicated for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and above. The launch marks Acrotech's entry into the U.S. dermatology market. Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech for U.S. commercialisation.
Why is Aurobindo Pharma in focus?
The product launch expands Acrotech's U.S. commercial portfolio and provides a company-specific development for investors tracking Aurobindo Pharma's specialty and branded-business opportunities.
Tech Mahindra
Tech Mahindra has received two additional orders in September with a combined value of ₹500.22 crore. The buildings division accounted for ₹224.74 crore, while the transportation division contributed ₹275.48 crore. Separately, the company's board is scheduled to meet on October 15 to consider an interim dividend for FY27 and a proposal for bonus shares. The board will also consider the company's audited standalone and consolidated Q2 and half-year FY27 results.
Why is Tech Mahindra in focus?
The October 15 board meeting could generate interest because it combines the company's Q2 FY27 results with potential corporate actions involving a bonus issue and interim dividend.
Highway Infrastructure
Highway Infrastructure has secured a ₹220.66 crore contract from the Uttar Pradesh Expressways Industrial Development Authority for user-fee collection and operation of toll plazas at the Gorakhpur Link Expressway. In another development, the company received a ₹24.46 crore LoA from the National Highways Authority of India for operations at Velanchettiyur Fee Plaza in Tamil Nadu.
Blue Dart Express and Symbiotec Pharma
Blue Dart Express announced a 9% to 12% general price increase across its domestic portfolio, effective January 1, 2027. The increase will vary based on the product and customer shipping profile.
Symbiotec Pharma's wholly owned subsidiary, Knovea Pharmaceutical, entered into an agreement with a leading global pharmaceutical company for exclusive U.S. commercialisation and distribution rights for two dual-chamber vial-based injectable products.
Lemon Tree Hotels and Bata India
Lemon Tree Hotels has expanded its portfolio in West Bengal with the opening of Keys Prima by Lemon Tree Hotels in Darjeeling. The 65-room property is managed by subsidiary Carnation Hotels and marks the group's first hotel in Darjeeling.
Bata India has appointed Sanjay Rao as Managing Director and CEO. He succeeds Gunjan Shah, who will complete his five-year tenure at the company.
IRFC and MCX
Indian Railway Finance Corporation has received a ₹396.9 crore Show Cause Notice from the Joint Commissioner of State Tax, Hajipur, Bihar, for FY23.
Multi Commodity Exchange of India has received a GST demand of ₹54.08 crore, along with ₹43.82 crore in interest, for FY23. The notice relates to allegations of tax being unpaid or short-paid and/or incorrect availment or utilisation of input tax credit.
Why is MCX in focus?
The GST notice is a regulatory development that could remain relevant as the company responds to the tax authorities.
Wipro, Infosys and Financial Stocks
Wipro has extended the deadline for its acquisition of select customer contracts of Alpha Net Consulting LLC to December 31, 2026.
Infosys and ABN AMRO Bank have extended their strategic collaboration focused on AI-driven transformation, application development, testing and support services.
Why is Infosys in focus?
The extension adds to Infosys' ongoing AI and digital-transformation engagement with a major banking client and comes ahead of the broader Q2 FY27 IT earnings season.
South Indian Bank appointed Mahesh Muralidhar Pai as Managing Director and CEO for three years effective October 1. DIC India also received shareholder approval for senior management appointments.
Jio Financial Services and Allianz Europe B.V. have each subscribed to 32 crore shares of Jio Allianz General Insurance at ₹10 per share through a rights issue. The ₹320.05 crore capital infusion will support the joint venture's business operations.
Why is Jio Financial Services in focus?
The capital infusion strengthens the funding base of Jio Allianz General Insurance as the joint venture develops its general insurance business in India.
Nifty Prediction Today: Market Setup for October 1
The company-specific developments above come against a weak broader-market backdrop.
Nifty 50 closed at 22,620.45 on September 30, down 0.42%, extending its decline for a third consecutive session.
For traders looking at the broader index setup alongside individual stocks, see our Nifty Prediction Today, October 1 article covering:
- Nifty support at 22,500–22,550
- Deeper support near 22,222
- 22,800–23,000 resistance
- 23,120 major resistance
- RSI and ADX readings
- Current technical trend
Stocks to Watch Today: FAQs
Aurobindo Pharma, Tech Mahindra, NCC, Highway Infrastructure, Blue Dart Express, Symbiotec Pharma, Lemon Tree Hotels, Bata India, IRFC, MCX, Wipro, Infosys, South Indian Bank and Jio Financial Services are among the stocks with notable corporate updates.
Aurobindo Pharma's subsidiary Acrotech Biopharma launched ADQUEY, a difamilast 1% ointment, in the U.S. for mild-to-moderate atopic dermatitis.
Tech Mahindra's board is scheduled to meet on October 15 to consider Q2 and half-year FY27 results, an interim dividend and a proposal for bonus shares.
NCC received two additional September orders worth ₹500.22 crore, taking its disclosed September order inflow to approximately ₹1,576.93 crore including the earlier ₹1,076.71 crore order.
IRFC received a ₹396.91 crore GST-related show-cause notice from Bihar tax authorities for FY23.
MCX received a GST show-cause notice proposing ₹54.08 crore in tax, ₹43.82 crore in interest and ₹5.41 crore in penalty for FY23.
Jio Financial Services and Allianz Europe each invested ₹320.05 crore in their 50:50 general insurance joint venture through a rights issue, resulting in combined capital infusion of ₹640.10 crore.
Investors tracking individual stocks should also monitor the broader Nifty trend, market breadth, crude oil prices, bond yields, foreign investor flows and major global market cues.
